ArticleJournal for immunotherapy of cancer2023
Response to "
Lilach Aizenbud, David A Schoenfeld, Jasmine I Caulfield, Jacqueline E Mann, Matthew R Austin, Ana Luisa Perdigoto, Kevan C Herold, Harriet M Kluger
Abstract readLetterComment
In one paragraphArticle in Journal for immunotherapy of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
8 authors.
Lilach AizenbudDepartment of Medicine (Medical Oncology), Yale University School of Medicine, New Haven, Connecticut, USA.
David A SchoenfeldDepartment of Medicine (Medical Oncology), Yale University School of Medicine, New Haven, Connecticut, USA.ORCID 0000-0002-5202-3744 Jasmine I CaulfieldDepartment of Medicine (Medical Oncology), Yale University School of Medicine, New Haven, Connecticut, USA.
Jacqueline E MannDepartment of Medicine (Medical Oncology), Yale University School of Medicine, New Haven, Connecticut, USA.
Matthew R AustinDepartment of Medicine (Medical Oncology), Yale University School of Medicine, New Haven, Connecticut, USA.
Ana Luisa PerdigotoDepartment of Medicine (Endocrinology and Metabolism), Yale University School of Medicine, New Haven, Connecticut, USA.
Kevan C HeroldDepartment of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
Harriet M KlugerDepartment of Medicine (Medical Oncology), Yale University School of Medicine, New Haven, Connecticut, USA Harriet.Kluger@Yale.edu.ORCID 0000-0002-4932-9873 Funding
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MYale SPORE in Skin CancerP50CA121974 · NCI · YALE UNIVERSITY · PI MARCUS W BOSENBERG, Harriet M. Kluger · 2006 to 2026
$43.9MYALE CANCER CENTER CALABRESI IMMUNO-ONCOLOGY TRAINING PROGRAMK12CA215110 · NCI · YALE UNIVERSITY · PI Harriet M. Kluger · 2018 to 2026
$6.1MYale Cancer Biology Training GrantT32CA193200 · NCI · YALE UNIVERSITY · PI PETER M GLAZER, Qin Yan · 2016 to 2026
$3.6MCytoplasmic cyclin E is an early event for progression to invasive breast cancerR01CA223772 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KEYOMARSI, KHANDAN · 2018 to 2023
$2.3MNCATS NIH HHS UL1 TR001863NCI NIH HHS K12 CA215110NCI NIH HHS P50 CA121974NCI NIH HHS R01 CA223772NCI NIH HHS T32 CA193200
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Immune Checkpoint InhibitorsNeoplasmsGerm CellsGerm-Line MutationHumansImmunityIntracellular Signaling Peptides and ProteinsImmune Checkpoint InhibitorsIntracellular Signaling Peptides and ProteinsNLRC5 protein, humangenetic markersimmune checkpoint inhibitors
Identifiers
PMID37349129
PMCPMC10314693
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390